Table 3.
Compotision of basal medium and expansion medium
| Basal medium (DMEM/F12) | |||
| Product | Company | Product number | Final concentration |
| DMEM/Ham's F–12 | Gibco | 12634–010 | |
| Pencillin–streptomycin | Gibco | 15140–122 | |
| HEPES | Nacalai Tesque | 17557–94 | 10 mM |
| Glutamax | Gibco | 35050–06 | 2 mM |
| Expansion medium (ExM) | |||
| Product | Company | Product number | Final concentration |
| Basal medium | 46.60% | ||
| B27 Supplement (50×) | Gibco | 2389219 | 2% |
| N–acetylcysteine | Wako | 015–05132 | 1 mM |
| Recombinant Human FGF10 | Peprotech | 100–26 | 10 ng/ml |
| Nicotinamide | Wako | 141–01202 | 10 mM |
| A83–01 | Nacalai Tesque | 19692–54 | 500 nM |
| SB202190 | Sigma | S7067 | 10 µM |
| Y–27632 | Wako | 034–24024 | 10 µM |
| Recombinant EGF | Peprotech | 100–15 | 50 ng/ml |
| Primocin | InvivoGen | ant–pm | 50 µg/ml |
| Afamin Wnt3A* | 50% | ||